Is Biogen a Bad-News Buy Now? [The Motley Fool]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: The Motley Fool
Is Biogen a Bad-News Buy Now? Wise drug developers say only fools rush in, but Biogen ( NASDAQ:BIIB Is the newly de-risked Biogen a good stock to buy following its clinical-trial disaster? Despite the recent loss, long-term investors have seen their shares gain ,00% over the past couple of decades. Let's take a look under the hood to see if this legendary biotech can do it again. Image source: Getty Images. Reasons to remain cautious With the exception of Spinraza, U.S. demand for Biogen's entire line of multiple sclerosis (MS) products is sliding. The number of Tecfidera capsules that Biogen shipped in the U.S. fell % last year. Even though Biogen raised the drug's list price, sales in the region fell %, to $. billion, as pharmacy benefit managers Novartis NYSE:NVS Biogen's Tysabri is a highly effective but dangerous drug reserved for severely relapsing MS patients and is getting pummeled by a new competitor. Ocrevus Roche NASDAQOTH:RHHBY Ocrevus looks like the safest MS treatment of
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- AI for drug discovery draws a $1 billion launch—and a lot of hope [Yahoo! Finance]Yahoo! Finance
- AI for drug discovery draws a $1 billion launch—and a lot of hope [Fortune]Fortune
- Xaira, an AI drug discovery startup, launches with a massive $1B, says it's ‘ready' to start developing drugs [TechCrunch]TechCrunch
- Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance